LFA
HRMY icon

LGT Financial Advisors’s Harmony Biosciences HRMY Stock Holding History

LGT Financial Advisors’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-87
Closed -$2.99K – 502
2024
Q4 		$2.99K Hold
87
– – 0.01% 640
2024
Q3 		$3.48K Hold
87
– – 0.01% 601
2024
Q2 		$2.63K Hold
87
– – 0.01% 709
2024
Q1 		$2.92K Hold
87
– – ﹤0.01% 703
2023
Q4 		$2.81K Buy
87
+11
+14% +$307 ﹤0.01% 744
2023
Q3 		$2.49K Buy
+76
New +$2.64K ﹤0.01% 775

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

LGT Financial Advisors's HRMY Position: Q1 2025 in Review

LGT Financial Advisors sold out of Harmony Biosciences (HRMY) in Q1 2025, closing a stake of 87 shares — an estimated $2.99K sold.

LGT Financial Advisors first reported a position in HRMY in Q3 2023 and held it in 6 quarters. The position peaked at $3.48K in Q3 2024. 272 funds tracked by Wall St. Rank hold HRMY as of Q1 2025.

  • LGT Financial Advisors reported no remaining Harmony Biosciences position as of Q1 2025 after selling out during the quarter.
  • LGT Financial Advisors sold 87 Harmony Biosciences shares in Q1 2025, an estimated $2.99K.
  • LGT Financial Advisors first reported a position in Harmony Biosciences in Q3 2023 and held it in 6 quarters.
  • LGT Financial Advisors's Harmony Biosciences position peaked at $3.48K in Q3 2024.
  • 272 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2025.

Based on LGT Financial Advisors's 13F filing for Q1 2025, filed 8 May 2025.